1) Acute bacterial skin and skin structure infections (ABSSSI): Ceftaroline is indicated for the treatment of ABSSSI caused by susceptible isolates of Gram-positive and Gram-negative microorganisms, including Staphylococcus aureus (both methicillin-resistant and methicillin-susceptible isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.
2) Community-acquired bacterial pneumonia (CABP): Ceftaroline is indicated for the treatment of CABP caused by susceptible isolates of Gram-positive and Gram-negative microorganisms, including Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.